▸Cancer Innovation is an interdisciplinary open access (OA) English journal supervised by the Ministry of Education, hosted by Tsinghua University, and published by Tsinghua University Press and Wiley.
▸Cancer Innovation is an English-language journal focusing on the frontiers of oncology medicine, which is committed to promoting the interdisciplinary intersection of medicine and engineering, informatics, pharmacy, biology and other disciplines, and guiding the interdisciplinary integration of oncology and cardiovascular, respiratory, neurological, reproductive and other specialties.
▸Cancer Innovation has been selected as the "2022 China Science and Technology Journal Excellence Action Plan High Starting Point New Journals Project", and has been included in the internationally renowned databases PubMed Central (PMC), Scopus, DOAJ, and CAS (American Chemical Abstracts).
▸Honorary Editor-in-Chief of Cancer Innovation is Academician Xu Binghe, Academician of the Chinese Academy of Engineering, Director of the National New Drug (Anti-tumor) Clinical Research Center of the National Cancer Center/Cancer Hospital of the Chinese Academy of Medical Sciences, Academician Zhan Qimin, Academician of the Chinese Academy of Engineering, Dean of the International Institute of International Cancer Research of Peking University, and Dean of the National Institute of Health and Medical Big Data of Peking University, and Academician Ding Jian, Academician of the Chinese Academy of Engineering and Academician of the Shanghai Institute of Materia Medica, Chinese Academy of Sciences. Professor Ma Fei from the Cancer Hospital of the Chinese Academy of Medical Sciences.
▸期刊发表论文类型多元，包括Original Article, Review, Clinical Guideline, Technical Report, Case Report, Commentary, News, Study Protocol, Meta-Analysis, Letter与Editorial。
▸ Waiver of page fees until 2025; Provide free, high-quality editing services for receiving articles; Adopt the free-form submission mode to reduce the burden on authors.
Vol.3 No.4 (2024.8)
Note: In this article, * indicates the corresponding author.
META-ANALYSIS
1
title
Efficacy and safety of first-line regimens for advanced HER2-positive breast cancer: A Bayesian network meta-analysis
Efficacy and safety of first-line regimens in advanced HER2-positive breast cancer: a Bayesian network meta-analysis
author
Lixi Li, Yun Wu, Bo Lan, Fei Ma*
Image abstract
We conducted a network meta-analysis to compare all treatment regimens from randomized controlled trials for advanced HER2-positive breast cancer in first-line setting.
How to quote
Li L, Wu Y, Lan B, Ma F. Efficacy and safety of first-line regimens for advanced HER2-positive breast cancer: a Bayesian network meta-analysis. Cancer Innov. 2024; 3:e126. https://doi.org/10.1002/cai2.126
ORIGINAL ARTICLES
2
title
Novel progressive deep learning algorithm for uncovering multiple single nucleotide polymorphism interactions to predict paclitaxel clearance in patients with nonsmall cell lung cancer
A novel progressive deep learning algorithm to reveal multiple single nucleotide polymorphism interactions in non-small cell lung cancer patients to predict paclitaxel clearance
author
Wei Chen, Haiyan Zhou, Mingyu Zhang, Yafei Shi, Taifeng Li, Di Qian, Jun Yang*, Feng Yu*, Guohui Li*
Image abstract
In this work, we successfully devised a potent deep-learning algorithm, called GEP-CSI, tailored for the nuanced mining of single nucleotide polymorphism (SNP) interactions, leveraging data on paclitaxel clearance and individual genetic polymorphism in patients with nonsmall cell lung cancer. Our analysis successfully identified and validated combinations of three SNPs that exhibited the highest fitness function values based on the GEP-CSI.
How to quote
Chen W, Zhou H, Zhang M, Shi Y, Li T, Qian D, et al. Novel progressive deep learning algorithm for uncovering multiple single nucleotide polymorphism interactions to predict paclitaxel clearance in patients with nonsmall cell lung cancer. Cancer Innov. 2024; 3:e110. https://doi.org/10.1002/cai2.110
3
title
A lactate-responsive gene signature predicts the prognosis and immunotherapeutic response of patients with triple-negative breast cancer
Lactate-responsive gene signatures predict prognosis and immunotherapy response in patients with triple-negative breast cancer
author
Kaixiang Feng, Youcheng Shao, Jun Li, Xiaoqing Guan, Qin Liu, Meishun Hu, Mengfei Chu, Hui Li, Fangfang Chen*, Zongbi Yi*, Jingwei Zhang*
Image abstract
The study was primarily conducted in three sequential steps: Step 1 involved generating a gene signature consisting of 14 lactate-responsive genes, Step 2 focused on exploring the features associated with this lactate-responsive gene signature, and Step 3 aimed to construct a consensus subtyping and risk evaluation system based on this gene signature.
How to quote
Feng K, Shao Y, Li J, Guan X, Liu Q, Hu M, et al. A lactate-responsive gene signature predicts the prognosis and immunotherapeutic response of patients with triple-negative breast cancer. Cancer Innov. 2024; 3:e124. https://doi.org/10.1002/cai2.124
4
title
Integrative analyses identified gap junction beta-2 as a prognostic biomarker and therapeutic target for breast cancer
A comprehensive analysis of breast cancer prognostic biomarkers and therapeutic targets "connexin β-2".
author
By Zhang, Lixi Li, Fei Ma*
Image abstract
Gap junction beta-2, a connexin protein, is overexpressed in various breast cancer subtypes and associated with poor prognosis. Notably, mutated Gap junction beta-2 is localized on the tumor cell membrane, while somatic mutations and copy number variations are rare. Gap junction beta-2 transcription levels were elevated in the p110α subunit of the phosphoinositide 3-kinase (PI3K) mutant subgroup, linking it to the PI3K-Akt signaling pathway, extracellular matrix–receptor interactions, focal adhesion, and proteoglycan regulation in cancer. Furthermore, Gap junction beta-2 overexpression predicted resistance to PI3K and histone deacetylase inhibitors and correlated with immune cell infiltration, including CD8+ T cells, macrophages, neutrophils, and dendritic cells. Gap junction beta-2 may serve as a dual therapeutic target for both targeted therapy and immunotherapy and could be a valuable predictor of breast cancer prognosis.
How to quote
Zhang D, Li L, Ma F. Integrative analyses identified gap junction beta-2 as a prognostic biomarker and therapeutic target for breast cancer. Cancer Innov. 2024; 3:e128. https://doi.org/10.1002/cai2.128
5
title
Synergistic effect of additional anlotinib and immunotherapy as second-line or later-line treatment in pancreatic cancer: A retrospective cohort study
Synergistic Effect of Allotinib with Immunotherapy as a Second- or Post-Line Treatment for Pancreatic Cancer: A Retrospective Cohort Study
author
Boyu Qin, Qi Xiong, Lingli Xin, Ke Li, Weiwei Shi, Qi Song, Qiong Sun, Jiakang Shao, Jing Zhang, Xiao Zhao, Jinyu Liu*, Jinliang Wang*, Bo Yang*
Image abstract
Anlotinib, especially anlotinib plus immunotherapy, has a potential added antitumor effect for patients with pancreatic ductal adenocarcinoma as a second- or later-line therapy with tolerable adverse events. The overall survival was 6.3 months in pancreatic ductal adenocarcinoma patients receiving additional anlotinib and was further prolonged when receiving addition of anlotinib and immunotherapy. Combination of immunotherapy and anlotinib has a synergetic effect, especially in patients with baseline red blood cell distribution width <14% and second-line treatment.
How to quote
Qin B, Xiong Q, Xin L, Li K, Shi W, Song Q, et al. Synergistic effect of additional anlotinib and immunotherapy as second-line or later-line treatment in pancreatic cancer: a retrospective cohort study. Cancer Innov. 2024; 3:e123. https://doi.org/10.1002/cai2.123
6
title
Identification of NR3C2 as a functional diagnostic and prognostic biomarker and potential therapeutic target in non-small cell lung cancer
NR3C2 as a functional diagnostic and prognostic biomarker for non-small cell lung cancer and identification of potential therapeutic targets
author
Yuan-yuan Sun, Hai-cheng Gao, Peng Guo, Na Sun, Chan Peng, Zhi-hua Cheng, Jing Gu, Jin-yi Liu*, Fei Han*
Image abstract
The altered expression and methylation of NR3C2 have clear and specific diagnostic and prognostic values in NSCLC, LUAD, and LUSC; NR3C2 expression should be regulated by copy number variations in NSCLC and LUAD, whereas regulated by promoter methylation in LUSC; NR3C2 is a functional key participant in NSCLC development, which is closely associated with tumor microenvironment, immune cell infiltration, and many cancers related-signaling pathways.
How to quote
Sun Y-y, Gao H-c, Guo P, Sun N, Peng C, Cheng Z-h, et al. Identification of NR3C2 as a functional diagnostic and prognostic biomarker and potential therapeutic target in non-small cell lung cancer. Cancer Innov. 2024; 3:e122. https://doi.org/10.1002/cai2.122
7
title
Identification of collagen subtypes of gastric cancer for distinguishing patient prognosis and therapeutic response
Identify collagen subtypes of gastric cancer to distinguish patient prognosis and response to treatment
author
Di Wang, Jing Zhang, Jianchao Wang, Zhonglin Cai, Shanfeng Jin, Gang Chen*
Image abstract
We classified gastric cancers into two subtypes based on collagen gene expression and validated these subtypes in three validation cohorts. The collagen subgroups exhibited differences in prognosis, clinical characteristics, transcriptome, and genetic alterations. The subtypes were closely related to patient response to chemotherapy, immunotherapy, and targeted therapy.
How to quote
Wang D, Zhang J, Wang J, Cai Z, Jin S, Chen G. Identification of collagen subtypes of gastric cancer for distinguishing patient prognosis and therapeutic response. Cancer Innov. 2024; 3:e125. https://doi.org/10.1002/cai2.125
8
title
High-fat-diet-induced obesity promotes simultaneous progression of lung cancer and atherosclerosis in apolipoprotein E-knockout mice
High-fat diet-induced obesity promotes simultaneous progression of lung cancer and atherosclerosis in apolipoprotein E knockout mice
author
Yihao Wang, Kaixin Yan, Han Duan, Ning Tao, Shaoning Zhu, Yuning Zhang, Yonggang You, Zhen Zhang, Hua Wang*, Shunying Hu*
Image abstract
Clinical studies showed that atherosclerotic cardiovascular disease (ASCVD) and cancer often coexist in the same individual. The study first showed that obesity could promote atherosclerosis burden as well as promote tumorigenesis and metastasis of lung cancer in the same individual mice. The results showed that obesity could contribute to the coexistence of atherosclerosis and lung cancer; so, screening both ASCVD and lung cancer would be significant in obese patients. LOX-1-related pathway likely was a significant contributor to the coexistence of atherosclerosis and lung cancer in the same individual. LOX-1 could be a target for the management of ASCVD and lung cancer in obese patients.
How to quote
Wang Y, Yan K, Duan H, Tao N, Zhu S, Zhang Y, et al. High-fat-diet-induced obesity promotes simultaneous progression of lung cancer and atherosclerosis in apolipoprotein E-knockout mice. Cancer Innov. 2024; 3:e127. https://doi.org/10.1002/cai2.127